Checkpoint Therapeutics, Inc. (CKPT)
Immune Check Activators Market: Growing Trade Among Emerging Economies Opening New Opportunities (2020-2027) | Genentech, Bristol-Myers Squibb, Checkpoint Therapeutics, Inc., GlaxoSmithKline Pharmaceuticals, Hoffmann-La Roche
Latest released the research study on Global Immune Check Activators Market, offers a detailed overview of the factors influencing the global business scope. Immune Check Activators Market research report shows the latest market insights, current situation analysis with upcoming trends
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Ardelyx Inc (NASDAQ: ARDX )(announced positive results for the Phase 3 study of tenapanor as monotherapy for treating hyperphosphatemia in patients with chronic kidney disease on dialysis) Audentes Therapeutics Inc (NASDAQ: BOLD )( announced a deal to be bought by ASTELLAS PHARMA/ADR (OTC: ALPMY )) Axsome Therapeutics Inc (NASDAQ: AXSM )(announced positive mid-stage readout for drug to treat narcolepsy) Cassava Sciences Inc (NASDAQ: SAVA ) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Inspire Medical Systems Inc (NYSE: INSP ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Recro Pharma Inc (NASDAQ: REPH ) Xenon Pharmaceuticals Inc (NASDAQ: XENE ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 3) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Evelo Biosciences Inc (NASDAQ: EVLO ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Neon Therapeutics Inc (NASDAQ: NTGN ) Orgenesis Inc (NASDAQ: ORGS ) Predictive Oncology Inc (NASDAQ: POAI ) Protagonist Therapeutics Inc (NASDAQ: PTGX )(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia) Therapix Biosciences …
Checkpoint Therapeutics, Inc. (CKPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
>40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT ), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive interim results from its ongoing multicenter Phase 1 clinical trial of cosibelimab (formerly referred to as CK-301). Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 ("PD-L1") and blocks the PD-L1 interaction with the programmed death receptor-1 ("PD-1") and B7.1 receptors. Cosibelimab is potentially differentiated from currently marketed PD-1 and PD-L1 antibodies with a half-life that supports sustained >99% tumor target occupancy and the additional benefit of a functional Fc domain capable of inducing antibody-dependent cell-mediated cytotoxicity ("ADCC") for potential enhanced efficacy in certain tumor types. "We are excited by the compelling efficacy demonstrated in the interim data of cosibelimab, with greater than 40% objective response rates in non-small cell lung cancer and cutaneous squamous cell carcinoma, as well as the strikingly high rate of patients with target lesion reductions across diverse tumor types," said James F.
CKPT: Disruptive Pricing Model to Fire Up $20B+ Market
Checkpoint Therapeutics (CKPT) will be releasing highly anticipated interim data from its Phase I clinical trial this quarter. The readout will be for CK-301, an anti-PD-L1 antibody, which is expected to include safety and efficacy data from approximately 40-50 patients with a variety of tumor types